Can further studies lower the cost of preserving vision?

The results of two large, randomized clinical trials published October 5, 2006, in the New England Journal of Medicine demonstrate that the drug ranibizumab is an effective treatment for neovascular macular degeneration, a complication of age-related macular degeneration that leads to the vast majority of legal blindness associated with the disorder.

If you want to include this story in your blog, copy and paste this formatted text:

<p><a href="http://www.physorg.com/news79204443.html">Can further studies lower the cost of preserving vision?</a></p> <p>The results of two large, randomized clinical trials published October 5, 2006, in the <i>New England Journal of Medicine</i> demonstrate that the drug ranibizumab is an effective treatment for neovascular macular degeneration, a complication of age-related macular degeneration that leads to the vast majority of legal blindness associated with the disorder.</p>